Neosporin

Ophthalmological Anti-infectives

For ophthalmic use only. Do not give by injection or orally.
Instruct patient on proper instillation of eye solution.
Wash hands before and after use. Tilt the head back slightly and pull the lower eyelid down with the index finger. Squeeze one drop into the conjunctival sac and gently apply pressure to the inside corner of your eye for 1 minute; this helps stop the liquid from draining down your tear duct. If you are prescribed more than 1 drop in the same eye, wait about 5 minutes between each drop.
Avoid contamination. Do not touch the tip of the dropper to the eye, fingertips, or other surface.
Patients should wait at least fifteen (15) minutes after instilling the eye solution before inserting contact lenses.
Do not share drops between patients.

anaphylactoid reactions / Rapid / 0-1.0

erythema / Early / 1.0-10.0
blurred vision / Early / 1.0-10.0
superinfection / Delayed / Incidence not known

ocular irritation / Rapid / 1.0-10.0
ocular pruritus / Rapid / 1.0-10.0

AK-Spore, AK-Spore Ophthalmic, Neocidin, Neosporin, Neosporin Ophthalmic Solution, Ocu-Spore-G, Polymycin

Rx

Aminoglycoside neomycin with polymyxin B and gramicidins A, B and C
Ophthalmic preparation; used for ophthalmic bacterial infections
Combination provides overlapping coverage against a wide range of gram-positive and gram-negative bacteria, including streptococci

1 to 2 drops in the affected eye(s) every 4 hours for 7 to 10 days; up to 2 drops in the affected eye(s) every hour for severe infections.

1 drop to the affected eye(s) every 5 to 15 minutes for 5 doses within 1 hour before the start of the procedure. Perioperative antisepsis with povidone-iodine is recommended. Subconjunctival or intracameral antibiotics at the end of the procedure is optional. The necessity of continuing topical antimicrobials postoperatively has not been established.

†Indicates off-label use

No dosage adjustment is needed.

No dosage adjustment is needed.

There are no drug interactions associated with Neomycin; Polymyxin B; Gramicidin products.

AK-Spore/AK-Spore Ophthalmic/Gramicidin, Neomycin, Polymyxin B/Neocidin/Neosporin/Ocu-Spore-G/Polymycin Ophthalmic Sol: 1mL, 0.025-1.75-10000U

Maximum dosage information not available.

Maximum dosage information not available.

Maximum dosage information not available.

Maximum dosage information not available; safety and efficacy have not been established.

Maximum dosage information not available; safety and efficacy have not been established.

Neomycin; polymyxin B; gramicidin is an ophthalmic solution for treating superficial infections of the external eye. The combined action of neomycin; polymyxin B; gramicidin is bactericidal.
Neomycin sulfate: Neomycin inhibits bacterial protein synthesis through irreversible binding to the 30 S ribosomal subunit of susceptible bacteria. Neomycin is actively transported into the bacterial cell where it binds to receptors present on the 30 S ribosomal subunit. This binding interferes with the initiation complex between the messenger RNA and the subunit. As a result, abnormal, nonfunctional proteins are formed due to misreading of the bacterial DNA. Eventually, susceptible bacteria die because of the lack of functional proteins.
Polymyxin B sulfate: Polymyxin B binds to gram-negative bacterial cell membrane phospholipids. This binding destroys bacterial membranes with a surface detergent-like mechanism and increases the permeability of the cell membrane, which results in loss of metabolites essential to bacterial existence. Polymyxin B has no in vitro activity against gram-positive organisms or fungi. The in vivo activity of polymyxin B against Pseudomonas aeruginosa is decreased by the presence of divalent cations such as calcium, which is believed to interfere with the binding of the drug to the cell membrane.
Gramicidin: Gramicidin is bactericidal against a variety of gram-positive bacteria. It increases the permeability of the bacterial cell membrane to inorganic cations. Gramicidin binds to bacterial cell membranes and forms a network of channels through the normal lipid bilayer.

Neomycin; polymyxin B; gramicidin combination products are applied topically to the eye.

Ophthalmic Route
Animal data suggest neomycin is absorbed into the aqueous humor, especially if the cornea is abraded. It is not known whether gramicidin or polymyxin B are absorbed into aqueous humor. Systemic absorption of these antibiotics after topical application to the eye is not likely to be significant.

No well-controlled studies of neomycin; polymyxin B; gramicidin have been conducted in pregnant women. The risk of fetal harm is considered unlikely because systemic absorption of these antibiotics is poor. However, health care providers should be aware that aminoglycosides, such as neomycin, cross the placenta and can cause fetal nephrotoxicity and permanent ototoxicity in infants whose mothers received them during pregnancy. It is not known whether gramicidin or polymyxin B can cause fetal harm during pregnancy. Use during pregnancy only if clearly needed.

Data are limited regarding use of neomycin; polymyxin B; gramicidin during breast-feeding. It should be noted that other aminoglycoside antibiotics have been found in breast milk. While systemic absorption is not significant with the ophthalmic product, the amount of drug that reaches systemic circulation and breast milk may be minimized by applying pressure over the tear duct by the corner of the eye for 1 minute after ophthalmic administration. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, health care providers are encouraged to report the adverse effect to the FDA.